TCDD reduces rat hepatic epidermal growth factor receptor: comparison of binding, immunodetection, and autophosphorylation.
Administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a potent tumor promoter, to rats resulted in a dose-dependent decrease in hepatic plasma membrane epidermal growth factor receptor (EGFR). The present study is the first to quantify and compare alterations in hepatic EGFR levels in female Sprague-Dawley rats 7 days after a single oral gavage dose of TCDD (0, 1, 5, 25, and 50 micrograms/kg) using three different techniques: (1) equilibrium receptor binding, (2) EGF induced receptor autophosphorylation, and (3) Western blot detection with a rabbit anti-rat EGFR polyclonal antibody. All three methods similarly demonstrated that the level of hepatic EGFR is significantly decreased at a dose of TCDD as low as 1 micrograms/kg. We showed that the immunoblot technique is a sensitive and quantitative alternative to radioligand binding assays. It is concluded that TCDD decreased total EGFR protein and maximum binding capacity without altering ligand binding affinity (Kd). The results demonstrated that ligand-induced autophosphorylation capacity and basal phosphotyrosine residues of plasma membrane EGFR were both decreased parallel with the decrease in EGFR protein, suggesting no TCDD-related alteration in the inherent functional ability of the receptor to undergo activation. Furthermore, it was found that the dose-response curve for EGFR protein level determined by Western blot analysis was similar for both male and female Sprague-Dawley rats.
Sewall
C H
CH
National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA.
Clark
G C
GC
Lucier
G W
GW
D000818:Animals; D001647:Bile Acids and Salts / Q000032:analysis; D015153:Blotting, Western; D003577:Cytochrome P-450 Enzyme System / Q000097:blood / Q000378:metabolism; D004790:Enzyme Induction; D004798:Enzymes / Q000097:blood; D066246:ErbB Receptors / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism*; D005260:Female; D008099:Liver / Q000033:anatomy & histology / Q000187:drug effects* / Q000648:ultrastructure; D008297:Male; D009929:Organ Size; D010766:Phosphorylation / Q000187:drug effects; D000072317:Polychlorinated Dibenzodioxins / Q000633:toxicity*; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012737:Sex Factors
D001647:Bile Acids and Salts; D004798:Enzymes; D000072317:Polychlorinated Dibenzodioxins; D003577:Cytochrome P-450 Enzyme System; D066246:ErbB Receptors